Advanced search
Publication Cover
Current Medical Research and Opinion Volume 20, 2004 - Issue 11
Submit an article Journal homepage
209
Views
35
CrossRef citations to date
0
Altmetric
Research Article

Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials

Andrew J. Palmer CORE - Center for Outcomes Research, Binningen/Basel, SwitzerlandCorrespondence[email protected]
,
Stéphane Roze CORE - Center for Outcomes Research, Binningen/Basel, Switzerland
,
William J. Valentine CORE - Center for Outcomes Research, Binningen/Basel, Switzerland
,
Inger Smith Novo Nordisk Limited, Crawley, UK
&
Kim U. Wittrup-Jensen Novo Nordisk A/S, Bagsværd, Denmark
Pages 1729-1746 | Accepted 08 Sep 2004, Published online: 24 Sep 2004

Citations (35)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

Jayne Smith-Palmer, Jay P Bae, Kristina S Boye, Kirsi Norrbacka, Barnaby Hunt & William J Valentine. (2016) Evaluating health-related quality of life in type 1 diabetes: a systematic literature review of utilities for adults with type 1 diabetes. ClinicoEconomics and Outcomes Research 8, pages 559-571.
Read now
Marc Evans, Phil McEwan & Volker Foos. (2015) Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice—a case-based evaluation. Journal of Medical Economics 18:2, pages 96-105.
Read now
Dong-Churl Suh & Mark Aagren. (2011) Cost–effectiveness of insulin detemir: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 11:6, pages 641-655.
Read now
Sandra L. Tunis, Michael E. Minshall, Christopher Conner, John I. McCormick, Jovana Kapor, Jean-François Yale & Danielle Groleau. (2009) Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis. Current Medical Research and Opinion 25:5, pages 1273-1284.
Read now
Jens Sandahl Christiansen. (2007) Insulin aspart: rapid control for postmeal glucose excursions. Expert Review of Endocrinology & Metabolism 2:5, pages 587-597.
Read now
Andrew J. Palmer, William J. Valentine, Joshua A. Ray, Volker Foos, Francesco Lurati, Inger Smith, Morten Lammert & Stéphane Roze. (2007) An economic assessment of analogue basal–bolus insulin versus human basal–bolus insulin in subjects with type 1 diabetes in the UK. Current Medical Research and Opinion 23:4, pages 895-901.
Read now
M. Hanefeld, A. Pfützner, T. Forst & G. Lübben. (2006) Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. Current Medical Research and Opinion 22:6, pages 1211-1215.
Read now

Articles from other publishers (28)

Hailey Saunders, Ba’ Pham, Desmond Loong, Sujata Mishra, Huda M. Ashoor, Jesmin Antony, Nazia Darvesh, Silkan K. Bains, Margaret Jamieson, Donna Plett, Srushhti Trivedi, Catherine H. Yu, Sharon E. Straus, Andrea C. Tricco & Wanrudee Isaranuwatchai. (2022) The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review. Value in Health 25:7, pages 1235-1252.
Crossref
Marc Evans, Roopa Mehta, Jens Gundgaard & Barrie Chubb. (2018) Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting. Diabetes Therapy 9:5, pages 1919-1930.
Crossref
Dalia Dawoud, Elisabetta Fenu, Bernard Higgins, David Wonderling & Stephanie A. Amiel. (2017) Basal Insulin Regimens for Adults with Type 1 Diabetes Mellitus: A Cost-Utility Analysis. Value in Health 20:10, pages 1279-1287.
Crossref
. (2017) Diabetes: The Big Picture (Vol. 21, No. 4, Full Issue). Asia-Pacific Biotech News 21:04.
Crossref
. (2017) FEATURES. Asia-Pacific Biotech News 21:04, pages 13-31.
Crossref
Asrul Akmal Shafie, Chin Hui Ng, Yui Ping Tan & Nathorn Chaiyakunapruk. (2016) Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus. PharmacoEconomics 35:2, pages 141-162.
Crossref
Marc Evans & Phil McEwan. (2015) Clinical and cost–effectiveness of insulin degludec: from clinical trials to clinical practice. Journal of Comparative Effectiveness Research 4:3, pages 279-286.
Crossref
Phil McEwan, Volker Foos, James L. Palmer, Mark Lamotte, Adam Lloyd & David Grant. (2014) Validation of the IMS CORE Diabetes Model. Value in Health 17:6, pages 714-724.
Crossref
Michèle Sennhauser & Peter Zweifel. (2014) Ist ein neues Arzneimittel sein Geld wert? Wessen Geld? – Bewertung eines neuen Diabetes-Präparats mit Hilfe eines Discrete-Choice-Experiments. PharmacoEconomics German Research Articles 11:2, pages 45-63.
Crossref
Ebenezer Tetteh & Stephen Morris. (2013) Systematic Review of Drug Administration Costs and Implications for Biopharmaceutical Manufacturing. Applied Health Economics and Health Policy 11:5, pages 445-456.
Crossref
W. J. Valentine, J. Jendle, M. Saraheimo, B. Thorsteinsson, R. F. Pollock & M. Lammert. (2012) Evaluating the cost‐effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands. Diabetic Medicine 29:3, pages 303-312.
Crossref
William J. Valentine, Mark Aagren, Mattias Haglund, Åsa Ericsson & Manuela H. Gschwend. (2010) Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden. Scandinavian Journal of Public Health 39:1, pages 79-87.
Crossref
Raquel Segovia Portolés, Juan C. Ferrer-García, Juan Francisco Merino-Torres, Maria T. Penalba, Raquel Albalat Galera & Francisco Piñón-Selles. (2010) Pauta óptima de administración de insulina detemir en sujetos diabéticos tipo 1 con mal control metabólico. Endocrinología y Nutrición 57:4, pages 140-146.
Crossref
Rui Li & Ping Zhang. 2010. The Evidence Base for Diabetes Care. The Evidence Base for Diabetes Care 449 470 .
Jason R. YoungCarrie Mcadam-Marx. (2010) Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog. Clinical Medicine Insights: Endocrinology and Diabetes 3, pages CMED.S5330.
Crossref
Sandra L. Tunis. (2009) A Cost-Effectiveness Analysis to Illustrate the Impact of Cost Definitions on Results, Interpretations and Comparability of Pharmacoeconomic Studies in the US. PharmacoEconomics 27:9, pages 735-744.
Crossref
Cosimo Giannini, Angelika Mohn & Francesco Chiarelli. (2009) Technology and the issue of cost/benefit in diabetes. Diabetes/Metabolism Research and Reviews 25:S1, pages S34-S44.
Crossref
Julia M. Bottomley & Frank D. Raymond. (2009) Pharmaco-economic issues for diabetes therapy. Insulin 4:1, pages 32-60.
Crossref
Moshe Vardi, Eyal Jacobson, Asaph Nini & Haim Bitterman. (2008) Intermediate acting versus long acting insulin for type 1 diabetes mellitus. Cochrane Database of Systematic Reviews.
Crossref
Luigi F Meneghini. (2008) Insulin detemir: a long-acting insulin analog for the treatment of Type 1 and 2 diabetes. Therapy 5:4, pages 513-529.
Crossref
Julia M. Bottomley & Frank D. Raymond. (2007) Pharmaco-economic issues for diabetes therapy. Best Practice & Research Clinical Endocrinology & Metabolism 21:4, pages 657-685.
Crossref
Todd P. Gilmer, Stéphane Roze, William J. Valentine, Katrina Emy-Albrecht, Joshua A. Ray, David Cobden, Lars Nicklasson, Athena Philis-Tsimikas & Andrew J. Palmer. (2007) Cost-Effectiveness of Diabetes Case Management for Low-Income Populations. Health Services Research 42:5, pages 1943-1959.
Crossref
David L. Russell-Jones. (2007) Insulin Detemir and Basal Insulin Therapy. Endocrinology and Metabolism Clinics of North America 36, pages 7-13.
Crossref
Javier Morales. (2007) Defining the Role of Insulin Detemir in Basal Insulin Therapy. Drugs 67:17, pages 2557-2584.
Crossref
Denis Daneman. (2006) Type 1 diabetes. The Lancet 367:9513, pages 847-858.
Crossref
William J. Valentine, Andrew J. Palmer, Katrina M. Erny-Albrecht, Joshua A. Ray, David Cobden, Volker Foos, Francisco M. Lurati & Stéphane Roze. (2006) Cost-effectiveness of basal insulin from a US health system perspective: Comparative analyses of detemir, glargine, and NPH. Advances in Therapy 23:2, pages 191-207.
Crossref
Dennis J. CadaTerri LevienDanial E. Baker. (2017) Insulin Detemir. Hospital Pharmacy 40:12, pages 1062-1074.
Crossref
S. Roze, W. J. Valentine, K. E. Zakrzewska & A. J. Palmer. (2005) Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK. Diabetic Medicine 22:9, pages 1239-1245.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.